or Try an Advanced Search...

    Technical Analysis for DNLI - Denali Therapeutics Inc.

    Grade Last Price % Change Price Change
    D 22.71 -2.57% -0.60
    DNLI closed up 1.17 percent on Wednesday, January 22, 2025, on approximately normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical DNLI trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish -2.57%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.57%
    Crossed Above 200 DMA Bullish -2.57%
    Spinning Top Other -2.57%
    Above Upper BB Strength -2.57%
    Overbought Stochastic Strength -2.57%
    Up 3 Days in a Row Strength -2.57%
    Up 4 Days in a Row Strength -2.57%
    Up 5 Days in a Row Strength -2.57%
    Upper Bollinger Band Touch Strength -2.57%
    Older End-of-Day Signals for DNLI ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 2 hours ago
    Down 3% about 2 hours ago
    Non-ADX 1,2,3,4 Bearish Retracement Entry about 2 hours ago
    Fell Below Previous Day's Low about 2 hours ago
    Down 2 % about 2 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    DNLI Chart by TradingView

    Profile

    Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Organ Systems Neuroscience Alzheimer's Disease Parkinson's Disease Neurological Disorders Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Degenerative Disease Neurodegeneration Senescence

    Is DNLI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 21 Denali Gains 26.6% in a Year: How Should You Play the Stock?
    Jan 17 Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential
    Jan 13 Denali Therapeutics sees cash runway into 2028
    Jan 13 Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
    Jan 9 Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
    Jan 9 DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
    Jan 8 Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome
    Jan 8 Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
    Jan 8 Denali Therapeutics price target lowered to $32 from $35 at BTIG
    Jan 7 Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
    See more DNLI news...

    Comments

    Indicators

    Indicator Value
    52 Week High 33.33
    52 Week Low 14.56
    Average Volume 984,074
    200-Day Moving Average 23.15
    50-Day Moving Average 23.53
    20-Day Moving Average 20.95
    10-Day Moving Average 21.13
    Average True Range 1.33
    RSI (14) 57.45
    ADX 18.3
    +DI 27.06
    -DI 23.35
    Chandelier Exit (Long, 3 ATRs) 19.69
    Chandelier Exit (Short, 3 ATRs) 22.52
    Upper Bollinger Bands 23.17
    Lower Bollinger Band 18.72
    Percent B (%b) 1.03
    BandWidth 21.25
    MACD Line -0.29
    MACD Signal Line -0.80
    MACD Histogram 0.5068
    Fundamentals Value
    Market Cap 3.35 Billion
    Num Shares 144 Million
    EPS -2.76
    Price-to-Earnings (P/E) Ratio -8.45
    Price-to-Sales 3339.01
    Price-to-Book 2.37
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 24.77
    Resistance 3 (R3) 24.73 24.21 24.52
    Resistance 2 (R2) 24.21 23.84 24.23 24.44
    Resistance 1 (R1) 23.76 23.61 23.99 23.80 24.36
    Pivot Point 23.24 23.24 23.35 23.26 23.24
    Support 1 (S1) 22.79 22.87 23.02 22.83 22.26
    Support 2 (S2) 22.27 22.64 22.29 22.18
    Support 3 (S3) 21.82 22.27 22.10
    Support 4 (S4) 21.86